Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 15/20 | 0.55 |
| ▸ | NPY4R | P50391 | 3/20 | 0.44 |
| ▸ | NPY1R | P25929 | 2/20 | 0.44 |
| ▸ | NPY2R | P49146 | 2/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18413053 | 1.00 | OPRK1 (0.55) | OPRK1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL20363353 | 0.92 | OPRK1 (0.57) | OPRK1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL13290902 | 0.92 | OPRK1 (0.59) | OPRK1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL11927498 | 0.91 | OPRK1 (0.60) | OPRK1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL20363364 | 0.90 | OPRK1 (0.63) | OPRK1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL13290894 | 0.90 | OPRK1 (0.57) | OPRK1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL21886314 | 0.90 | OPRK1 (0.57) | OPRK1OPRM1OPRD1 | |
| SCHEMBL10316406 | 0.90 | OPRK1 (0.57) | OPRK1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL11927497 | 0.89 | OPRK1 (0.47) | OPRK1OPRM1OPRD1 | |
| SCHEMBL11927495 | 0.87 | OPRK1 (0.55) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-10913769-B2 | Synthetic peptide amides and dimers thereof | CARA THERAPEUTICS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | ACER THERAPEUTICS INC. | 2021-02-04 | — | — | US | disclosed |
| WO-2020056249-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS, INC. (US) | 2020-03-19 | — | — | WO | disclosed |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-08-22 | — | — | US | disclosed |
| US-10017536-B2 | Synthetic peptide amides and dimers thereof | CARA THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170231979-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2017-08-17 | — | — | US | disclosed |
| US-20170020855-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2017-01-26 | — | — | US | disclosed |
| US-7842662-B2 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842662-B2 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7713937-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713937-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885NPY4R 502/4885NPY1R 613/4885 |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885NPY4R 502/4885NPY1R 613/4885 |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885NPY4R 43/4885NPY1R 9/4885 |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885NPY4R 502/4885NPY1R 613/4885 |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OGFR | OPRK1 1/4885NPY4R 118/4885NPY1R 89/4885 |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRM1, OPRL1 | OPRK1 1/4885NPY4R 29/4885NPY1R 6/4885 |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | OPRK1, OPRD1, OGFR | OPRK1 1/4885NPY4R 1068/4885NPY1R 363/4885 |
| US-10913769-B2 | Synthetic peptide amides and dimers thereof | OPRK1, OPRL1, OPRM1 | OPRK1 1/4885NPY4R 46/4885NPY1R 35/4885 |
| US-20170231979-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885NPY4R 502/4885NPY1R 613/4885 |
| US-20170020855-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885NPY4R 502/4885NPY1R 613/4885 |
| US-10017536-B2 | Synthetic peptide amides and dimers thereof | OPRK1, OPRL1, OPRM1 | OPRK1 1/4885NPY4R 46/4885NPY1R 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.